drugset / Trial / NCT02448303
Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Pembrolizumab alone and in combination with acalabrutinib in subjects with advanced non-small cell lung cancer.
Timeline
- Start
- 2015-05
- Primary completion
- 2018-03
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |